Is IMRX or INAB more undervalued in 2026?

CirclFi compares Immuneering Corporation (IMRX) and IN8bio, Inc. (INAB) using 13 institutional-grade valuation models. IMRX has a Quality of Company score of 4.5/10 while INAB scores 3.2/10.

Which is a better buy — IMRX or INAB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMRX and INAB valuations compare?

IMRX at $5.06 and INAB at $1.80 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMRX vs INAB Valuation Comparison 2026 — Intrinsic Value Analysis

IMRX

Biotechnology

Immuneering Corporation

Quality

4.5

out of 10

Value Trap

LOW

Price

$5.06

Last close

Models

7/13

Active

INAB

Biotechnology

IN8bio, Inc.

Quality

3.2

out of 10

Value Trap

LOW

Price

$1.80

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	IMRX Fair Value	IMRX Upside	INAB Fair Value	INAB Upside
Bayesian DCF	Intrinsic	$1.74	-65.7%	$1.60	-10.9%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.66	-67.2%	$0.21	-85.8%
Dynamic NAV	Asset-Based	$2.65	-47.7%	$3.60	+99.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMRX vs INAB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMRX vs INAB — Which Stock Is More Undervalued?

IMRX scores higher with a 4.5/10 quality rating vs INAB's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immuneering Corporation (IMRX) and IN8bio, Inc. (INAB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMRX currently trades at $5.06 with a QOC of 4.5/10, while INAB trades at $1.80 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).